Foxwell A Ruth, Kyd Jennelle M, Cripps Allan W
Gadi Research Centre for Medical and Health Sciences, University of Canberra, Canberra ACT 2601, Australia.
Expert Rev Vaccines. 2003 Aug;2(4):551-60. doi: 10.1586/14760584.2.4.551.
Bacterial respiratory diseases remain a major cause of morbidity and mortality throughout the world. The young and the elderly are particularly susceptible to the pathogens that cause these diseases. Therapeutic approaches remain dependent upon antibiotics contributing to the persistent increases in antibiotic resistance. The main causes of respiratory disease discussed in this review are Mycobacterium tuberculosis, Corynebacterium diphtheriae, Bordatella pertussis, Streptococcus pneumoniae, non-typeable Haemophilus influenzae, Moraxella catarrhalis and Pseudomonas aeruginosa. All these organisms initiate disease at the mucosal surface of the respiratory tract and thus the efficacy of the host's response to infection needs to be optimal at this site. Vaccines available for diseases caused by many of these pathogens have limitations in accessibility or efficacy, highlighting the need for improvements in approaches and products. The most significant challenges in both therapy and prevention of disease induced by bacteria in the respiratory tract remain the development of non-injectable vaccines and delivery systems/immunization regimens that improve mucosal immunity.
细菌性呼吸道疾病仍然是全球发病和死亡的主要原因。年轻人和老年人尤其易受引发这些疾病的病原体感染。治疗方法仍然依赖抗生素,这导致抗生素耐药性持续增加。本综述讨论的呼吸道疾病主要病因包括结核分枝杆菌、白喉棒状杆菌、百日咳博德特氏菌、肺炎链球菌、不可分型流感嗜血杆菌、卡他莫拉菌和铜绿假单胞菌。所有这些病原体均在呼吸道黏膜表面引发疾病,因此宿主对感染的反应在该部位的效果需要达到最佳。针对许多这些病原体所致疾病的现有疫苗在可及性或效力方面存在局限性,这凸显了改进方法和产品的必要性。在治疗和预防呼吸道细菌感染性疾病方面,最重大的挑战仍然是开发非注射型疫苗以及能够增强黏膜免疫力的递送系统/免疫方案。